echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Immunology News > ASCO's 5-year survival rate for specific lung cancer patients is 43%. PD-L...

    ASCO's 5-year survival rate for specific lung cancer patients is 43%. PD-L...

    • Last Update: 2021-06-12
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On June 5th, AstraZeneca announced that its blockbuster PD-L1 inhibitor Imfinzi (durvalumab) has shown significant results in a phase 3 clinical trial for the treatment of stage III non-small cell lung cancer (NSCLC) Long-term efficacy.


    Lung cancer is the leading cause of cancer deaths worldwide, and 80-85% of patients are NSCLC.


    Imfinzi is a humanized anti-PD-L1 monoclonal antibody.


    In a phase 3 clinical trial called PACIFIC, patients with stage III unresectable NSCLC who did not progress after chemotherapy and radiotherapy (CRT) were treated with Imfinzi or placebo.


    Dr.


    Reference materials:

    Reference materials:

    [1] Imfinzi demonstrated unprecedented survival in unresectable, Stage III lung cancer with 43% of patients surviving five years.


    [1] Imfinzi demonstrated unprecedented survival in unresectable, Stage III lung cancer with 43% of patients surviving five years.


    ▽ attention [drug Mingkang Germany ] micro-channel public number

    [Medical attention Mingkang Germany ] ] micro-channel public number

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.